Lupin Ltd's Ankleshwar plant receives two observations from the U.S. FDA after inspection. The company promises to address the issues while adhering to CGMP standards for quality and safety.
Pfizer reported positive results for its experimental eczema drug tilrekimig after it met the main goal in a Phase 2 trial for moderate-to-severe atopic dermatitis. The company now plans to move the treatment into late-stage Phase 3 testing.
Sun Pharmaceutical has announced the acquisition of US oncology company Checkpoint Therapeutics for $355 million, including FDA-approved skin cancer drug UNLOXCYT, strengthening its global cancer treatment portfolio.
Novo Nordisk is gaining momentum in India’s obesity drug market as semaglutide sales rise following price cuts and wider availability. The move is helping the company narrow the lead held by Eli Lilly’s tirzepatide in the fast-growing GLP-1 segment.
.png "Indian CDMOs Ramp Up Capacity to Meet Demand for Complex Drugs")
CDMOs are stepping up investments and expanding facilities as global pharma turns to them for complex drug development. Advanced therapies and biologics are driving this surge.
HLL Lifecare is expanding its Amrit Pharmacy network to 550 outlets by 2027, making affordable medicines and health products accessible in tier-2 and tier-3 cities across India.
Dr Reddy’s Laboratories receives USFDA EIR for Srikakulam facility after GMP and PAI inspection, strengthening regulatory compliance and global pharma manufacturing credibility.
Fujifilm India has launched endoscopy manufacturing in Jodhpur, marking a major step toward local production of advanced medical devices. The move supports Make in India and aims to improve access to diagnostic technology.
Alembic Pharmaceuticals achieves a milestone with the prescription-based sale of Pivya, a first-line oral antibiotic for UTI treatment, marking a key growth in global markets.
Novo Nordisk’s blockbuster diabetes drug is set to reshape India’s pharma market as the semaglutide patent expiry approaches. More than 50 companies are preparing generic versions, triggering a major race in the obesity and diabetes drug segment.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")